AU2012245439B2 - Endoglin polypeptides and uses thereof - Google Patents

Endoglin polypeptides and uses thereof Download PDF

Info

Publication number
AU2012245439B2
AU2012245439B2 AU2012245439A AU2012245439A AU2012245439B2 AU 2012245439 B2 AU2012245439 B2 AU 2012245439B2 AU 2012245439 A AU2012245439 A AU 2012245439A AU 2012245439 A AU2012245439 A AU 2012245439A AU 2012245439 B2 AU2012245439 B2 AU 2012245439B2
Authority
AU
Australia
Prior art keywords
eng
seq
polypeptide
heng
endoglin polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012245439A
Other languages
English (en)
Other versions
AU2012245439A1 (en
Inventor
Roselyne CASTONGUAY
Asya Grinberg
Ravindra Kumar
Eric Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2012245439A1 publication Critical patent/AU2012245439A1/en
Priority to AU2017201711A priority Critical patent/AU2017201711B2/en
Application granted granted Critical
Publication of AU2012245439B2 publication Critical patent/AU2012245439B2/en
Priority to AU2019204979A priority patent/AU2019204979B2/en
Priority to AU2020244456A priority patent/AU2020244456A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012245439A 2011-04-20 2012-04-19 Endoglin polypeptides and uses thereof Ceased AU2012245439B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017201711A AU2017201711B2 (en) 2011-04-20 2017-03-13 Endoglin polypeptides and uses thereof
AU2019204979A AU2019204979B2 (en) 2011-04-20 2019-07-11 Endoglin polypeptides and uses thereof
AU2020244456A AU2020244456A1 (en) 2011-04-20 2020-09-30 Endoglin polypeptides and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477585P 2011-04-20 2011-04-20
US61/477,585 2011-04-20
PCT/US2012/034295 WO2012145539A1 (en) 2011-04-20 2012-04-19 Endoglin polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017201711A Division AU2017201711B2 (en) 2011-04-20 2017-03-13 Endoglin polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2012245439A1 AU2012245439A1 (en) 2013-11-28
AU2012245439B2 true AU2012245439B2 (en) 2017-04-06

Family

ID=46000405

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012245439A Ceased AU2012245439B2 (en) 2011-04-20 2012-04-19 Endoglin polypeptides and uses thereof
AU2017201711A Ceased AU2017201711B2 (en) 2011-04-20 2017-03-13 Endoglin polypeptides and uses thereof
AU2019204979A Ceased AU2019204979B2 (en) 2011-04-20 2019-07-11 Endoglin polypeptides and uses thereof
AU2020244456A Abandoned AU2020244456A1 (en) 2011-04-20 2020-09-30 Endoglin polypeptides and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017201711A Ceased AU2017201711B2 (en) 2011-04-20 2017-03-13 Endoglin polypeptides and uses thereof
AU2019204979A Ceased AU2019204979B2 (en) 2011-04-20 2019-07-11 Endoglin polypeptides and uses thereof
AU2020244456A Abandoned AU2020244456A1 (en) 2011-04-20 2020-09-30 Endoglin polypeptides and uses thereof

Country Status (8)

Country Link
US (3) US9932386B2 (OSRAM)
EP (2) EP2699590B8 (OSRAM)
JP (3) JP6250533B2 (OSRAM)
CN (3) CN103781798B (OSRAM)
AU (4) AU2012245439B2 (OSRAM)
CA (1) CA2833747C (OSRAM)
DK (1) DK2699590T3 (OSRAM)
WO (1) WO2012145539A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN103781798B (zh) 2011-04-20 2018-03-13 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
JP2014524417A (ja) * 2011-08-01 2014-09-22 タフツ メディカル センター インコーポレイテッド 心不全および関連状態の処置
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
WO2015042269A1 (en) * 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
EA035481B1 (ru) * 2013-10-25 2020-06-23 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
CN105934249A (zh) 2013-11-21 2016-09-07 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN120514834A (zh) 2014-03-28 2025-08-22 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
EP3693004A1 (en) 2014-08-01 2020-08-12 The Brigham and Women's Hospital, Inc. An inhibitor of gdf-15 for use in treating fibrosis
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
CN110498851B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物及应用
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
CA3029890A1 (en) * 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
SI3628049T1 (sl) 2017-05-04 2023-10-30 Acceleron Pharma Inc. Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
US20210107959A1 (en) * 2018-01-03 2021-04-15 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
WO2020219796A1 (en) * 2019-04-26 2020-10-29 Vanderbilt University Probes for detecting rna and methods of use thereof
EP4009953A4 (en) * 2019-08-07 2023-08-23 Icahn School of Medicine at Mount Sinai METHOD OF TREATMENT OF KELOIDS
US20230285506A1 (en) * 2019-12-03 2023-09-14 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
US20220233714A1 (en) * 2021-01-27 2022-07-28 Vanderbilt University Nanogold-dna bioconjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
CA2147754A1 (en) * 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI1695985T1 (sl) 1997-04-07 2011-06-30 Genentech Inc Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ATE363291T1 (de) 2000-06-23 2007-06-15 Bayer Schering Pharma Ag Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1638941B1 (en) 2003-05-22 2010-06-02 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20090170767A1 (en) * 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
MX2009004718A (es) * 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
CA2685306A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US20100210713A1 (en) 2009-01-16 2010-08-19 The General Hospital Corporation Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
KR101805201B1 (ko) * 2009-03-30 2017-12-05 악셀레론 파마 인코포레이티드 Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
EP2427494B1 (en) 2009-05-08 2017-10-18 Novartis AG Methods of modulating fibrosis using bone morphogenetic protein-9 (bmp-9) modulators
WO2011088047A1 (en) * 2010-01-12 2011-07-21 Beth Israel Deaconess Medical Center Soluble endoglin and uses thereof
CN103781798B (zh) 2011-04-20 2018-03-13 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
JP2014524417A (ja) 2011-08-01 2014-09-22 タフツ メディカル センター インコーポレイテッド 心不全および関連状態の処置
WO2015042269A1 (en) 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
EA035481B1 (ru) 2013-10-25 2020-06-23 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途

Also Published As

Publication number Publication date
JP2018070625A (ja) 2018-05-10
JP7097930B2 (ja) 2022-07-08
US20210300991A1 (en) 2021-09-30
EP2699590B8 (en) 2019-04-17
DK2699590T3 (en) 2019-05-06
AU2020244456A1 (en) 2020-10-29
AU2017201711B2 (en) 2019-04-18
CN108178789B (zh) 2021-11-02
CN108341863A (zh) 2018-07-31
EP3549952A1 (en) 2019-10-09
AU2017201711A1 (en) 2017-04-13
WO2012145539A1 (en) 2012-10-26
AU2019204979B2 (en) 2020-07-16
JP2014513951A (ja) 2014-06-19
CA2833747A1 (en) 2012-10-26
US20150307588A1 (en) 2015-10-29
US20180258156A1 (en) 2018-09-13
JP2020202844A (ja) 2020-12-24
JP6803315B2 (ja) 2020-12-23
AU2019204979A1 (en) 2019-08-01
US9932386B2 (en) 2018-04-03
AU2012245439A1 (en) 2013-11-28
CN108178789A (zh) 2018-06-19
CA2833747C (en) 2022-10-18
EP2699590A1 (en) 2014-02-26
CN103781798A (zh) 2014-05-07
US10981972B2 (en) 2021-04-20
CN103781798B (zh) 2018-03-13
JP6250533B2 (ja) 2017-12-20
EP2699590B1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
US10981972B2 (en) Endoglin polypeptides and uses thereof
US11590201B2 (en) Endoglin peptides to treat fibrotic diseases
US20210002342A1 (en) Bmprii polypeptides and uses thereof
HK40055818A (en) Endoglin peptides to treat fibrotic diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired